This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
review in Europe, as well as oncolytic virus therapy Imlygic (talimogene laherparepvec), approved in the US in October.
Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot
Amgen's Imlygic (talimogene laherparepvec) is seeking an indication for the treatment of adults with unresectable melanoma that is regionally or distantly metastic (stage IIIB, IIIC and IVM1a).
Amgen and Merck have expanded their collaboration to evaluate the efficacy and safety of Amgen's talimogene laherparepvec in combination with Merck's Keytruda. ... Talimogene laherparepvec and Keytruda are designed to result in anti-tumour immune
Earlier, the company also signed an expanded deal to test Amgen's oncolytic virus therapy talimogene laherparepvec with Keytruda in head and neck cancer.
Big pharma deals. Meanwhile, Amgen has announced a tie-up with Roche w ith the two firms' investigational medicines talimogene laherparepvec and atezolizumab. ... Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to
More from news
Approximately 4 fully matching, plus 13 partially matching documents found.